What Researchers Did
Researchers conducted a narrative literature review to compile evidence on the use of hyperbaric oxygen therapy (HBO2) in sepsis and determine if human trials are indicated.
What They Found
The review identified several potential beneficial mechanisms of HBO2 therapy in sepsis, including improved mitochondrial and microvascular function, decreased capillary leak, and enhanced antibiotic effects. Animal studies suggest HBO2 may be most effective when administered early and in high doses, potentially reducing organ failure and preventing bacterial translocation in the gut.
What This Means for Canadian Patients
While currently experimental for sepsis, hyperbaric oxygen therapy shows promise as a future treatment option for Canadian patients suffering from this life-threatening condition. Further research, including human trials, is needed to determine if this therapy can improve clinical outcomes and reduce organ failure in Canadian patients with sepsis.
Canadian Relevance
This review did not have a direct Canadian connection, as it focused on compiling global evidence for hyperbaric oxygen therapy in sepsis.
Study Limitations
A key limitation is that this narrative review primarily synthesizes evidence from animal studies, indicating a need for human trials to confirm efficacy and safety.